Human fibrinogen concentrate (CSL Behring)

N/A

Report date: 2024/12/27 10:50:22

Base Information

Drug NameHuman fibrinogen concentrate (CSL Behring)
Drug Alias NameRiaSTAPHaemocomplettan PCSL-511
ClassificationBiologics > Blood components
Mechanisms of ActionFibrin modulatorsFibrinogen replacements
TargetsFibrinogen
Therapy Area/IndicationsWounds and InjuriesPostoperative HemorrhageBlood Loss, Surgical +[11] 
Global Approved IndicationsAfibrinogenemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2009/01/16
Country/TerritoryCzechiaCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCsl Behring Llc
China Registration ClassN/A

Develop Information

Active CompaniesCsl BehringEmory University
Inactive CompaniesUniversity of Sao PauloYale University
Active IndicationsHemorrhageAfibrinogenemiaPseudomyxoma Peritonei
Inactive IndicationsWounds and InjuriesPostoperative HemorrhageBlood Loss, Surgical +[8] 

Other Information

ATC CodeB02BB01
Related LinksWikipediaDrugBankKEGG